

PREVDUO®

(neostigmine methylsulfate and glycopyrrolate)
Injection—Prefilled Syringes



Simplify Your Workflow

Recommended dosing ratio^{1*}
for two FDA-approved products,
neostigmine methylsulfate and glycopyrrolate,
in one prefilled syringe

**FIRST AND ONLY FDA-APPROVED NEOSTIGMINE
METHYLSULFATE AND GLYCOPYRROLATE COMBINATION
PRODUCT AVAILABLE IN THE US²**

- ✓ Two-year shelf life^{3†} may offer enhanced inventory management
- ✓ Does not require compounding, diluting, mixing, or transferring, which may reduce waste⁴
- ✓ Aligns with medication strategies of *ASHP Guidelines on Preventing Medication Errors in Hospitals*⁴
- ✓ Compatible with most automated dispensing machines

*3 mg/3 mL (1 mg/mL) of neostigmine methylsulfate and 0.6 mg/3 mL (0.2 mg/mL) of glycopyrrolate.⁵

[†]When stored at the recommended storage condition of 20°C to 25°C (68°F to 77°F), protected from light. Store in carton until time of use.⁵

Product Name	NDC	Neostigmine Methylsulfate Concentration	Glycopyrrolate Concentration	Pack Size	Order Entry Number	
PREVDUO® (neostigmine methylsulfate and glycopyrrolate) Injection	42023-269-05	3 mg/3 mL (1 mg/mL)	0.6 mg/3 mL (0.2 mg/mL)	5 x 3 mL single-dose prefilled syringes	Cencora	10280291
					Cardinal	5849005
					McKesson	2819167
					M&D	281584
					Henry Schein	1438760
					McKesson Medical-Surgical	1232614

M&D=Morris & Dickson; NDC=National Drug Code.

Scan to
learn more



SIMPLIFYING YOUR WORKFLOW PREPARATION

ONE Step with Prefilled Syringe



VS

TEN Steps Using Standard Vial



1 Flip off cap of neostigmine methylsulfate vial



2 Swab vial with isopropyl alcohol



3 Withdraw appropriate amount of neostigmine methylsulfate



4 Label syringe



5 Inject intravenously



6 Flip off cap of glycopyrrolate vial



7 Swab vial with isopropyl alcohol



8 Withdraw appropriate amount of glycopyrrolate



9 Label syringe



10 Inject intravenously

Please click for full [Prescribing Information](#).

PREVDUO®
(neostigmine methylsulfate and glycopyrrolate) Injection

FIRST AND ONLY FDA-APPROVED NEOSTIGMINE METHYLSULFATE AND GLYCOPYRROLATE COMBINATION PRODUCT AVAILABLE IN THE US²



References: 1. Howard J, Wigley J, Rosen G, D'mello J. Glycopyrrolate: it's time to review. *J Clin Anesth.* 2017;36:51-53. 2. US Food and Drug Administration. Approved drug products with therapeutic equivalence evaluations. 45th ed. <https://www.fda.gov/media/71474/download?attachment>. Accessed June 4, 2025. 3. Data on file. DOF-PRVD-01. Endo USA, Inc.; July 20, 2023. 4. Billstein-Leber M, Carrillo CJD, Cassano AT, Moline K, Robertson JJ. ASHP guidelines on preventing medication errors in hospitals. *Am J Health-Syst Pharm.* 2018;75(19):1493-1517. 5. PREVDUO®. Prescribing Information. Endo USA, Inc.



PREVDUO® is a registered trademark of Azurity Pharmaceuticals, Inc.
© 2025 Endo, Inc. or one of its affiliates. All rights reserved.
EIS-PRVD-05012/July 2025 www.endo.com | www.TruDelivery.com